Alprostadil 150 MCG/ML Injectable recalled over sterility concerns
- Recall date
- January 15, 2020
- Source
- U.S. Food & Drug Administration (FDA) — enforcement report
- Official notice title
- Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical recalls Alprostadil (prostaglandin E1)150 MCG/ML Injectable, For Intracavernosal Use, Freeze, 2.5 mL Multi-dose Vial, Rx only,…
- Recall number
- D-0935-2020
- FDA classification
- Class II
- Brand / firm
- Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical
- Sold / distributed
- U.S.A. Nationwide and Puerto Rico, Barbados and Dominican Republic
Why it was recalled
Lack of Assurance of Sterility
Class II means using this product may cause temporary or medically reversible health problems; the chance of serious harm is remote.
What was recalled
Alprostadil (prostaglandin E1)150 MCG/ML Injectable, For Intracavernosal Use, Freeze, 2.5 mL Multi-dose Vial, Rx only, Axia Pharmaceutical 1990 Westwood Blvd. Ste 135, Los Angeles, CA 90025; NDC 71283-0538-2
Get recall alerts
Free email alert whenever Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical has a new recall — straight from official government data. Unsubscribe anytime.
More recalls from: Fusion IV Pharmaceuticals, Inc. dba Axia Pharmaceutical